COMMUNIQUÉS West-GlobeNewswire

BOAZ Pharmaceuticals Inc. Celebrates Sales Licence Granted In Record Time
25/05/2019
Passionate Team of Homegrown Heroes Proves Size Doesn’t Matter CALGARY, Alberta, May 24, 2019 (GLOBE NEWSWIRE) -- BOAZ Pharmaceuticals Inc. is now licensed to sell handcrafted cannabis in Canada to medical clients and [...]
Aptose Biosciences Establishes New At-The-Market Facility
24/05/2019
SAN DIEGO and TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019
WALTHAM, Mass. and CRESTWOOD, Ky., May 24, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors
24/05/2019
Montrouge, France, May 24, 2019 DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors Shareholders approve all proposed [...]
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2019, ainsi que la nomination de Madame Viviane Monges en tant que membre du conseil d’administration
24/05/2019
Montrouge, France, le 24 Mai 2019 (22h30 CET) DBV Technologies annonce les résultats de son Assemblée générale ordinaire et extraordinaire 2019, ainsi que la nomination de Madame Viviane Monges en tant que membre du [...]
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24/05/2019
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone in the SOLAR-1 [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019
BOTHELL, Wash., May 24, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
24/05/2019
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies expected over next three quarters- [...]
HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/05/2019
TUCSON, Ariz., May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the [...]
HEXO Corp and Newstrike Brands Ltd. Announce Closing of Arrangement
24/05/2019
GATINEAU, Quebec and OAKVILLE, Ontario , May 24, 2019 (GLOBE NEWSWIRE) -- HEXO Corp (" HEXO ") (TSX: HEXO; NYSE-A: HEXO) and Newstrike Brands Ltd. (" Newstrike ") (TSX-V: HIP) are pleased to announce that they have [...]
HEXO Corp et Newstrike Brands Ltd. annoncent la clôture de l’arrangement
24/05/2019
GATINEAU, Québec et OAKVILLE, Ontario , 24 mai 2019 (GLOBE NEWSWIRE) -- Hexo Corp (« HEXO ») (TSX: HEXO; NYSE-A: HEXO) et Newstrike Brands Ltd. (« Newstrike ») (TSX-V: HIP) ont le plaisir d’annoncer la conclusion de l’ [...]
Medtronic Chairman and CEO Omar Ishrak to Speak at Bernstein Strategic Decisions Conference
24/05/2019
DUBLIN - May 24, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 [...]
JDRF welcomes Disability Advisory Committee’s recommendation that all Canadians needing life-sustaining therapy should automatically meet the criteria for the Disability Tax Credit and urges the Government to adopt this approach
24/05/2019
TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Disability Advisory Committee’s (DAC) First Annual Report , in particular, [...]
SPINEWAY : Convocation Assemblée Générale Mixte des Actionnaires Spineway du 28 juin 2019
24/05/2019
Convocation Assemblée Générale Mixte des Actionnaires Spineway le 28 juin 2019 Modalités de mise à disposition des documents préparatoires Spineway informe ses actionnaires qu’ils sont convoqués en Assemblée Générale [...]
VitalHub Reports Positive Earnings in Q1 2019
24/05/2019
TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and [...]
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
24/05/2019
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD 425,000 per year for 5 years: [...]
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
24/05/2019
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2] Zolgensma ( [...]
IBA - Transparency notification
24/05/2019
Louvain-la-Neuve, Belgium, May 24, 2019, 17.35 Summary of the notification IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to [...]
IBA – Publication relative à une notification de transparence
24/05/2019
Louvain-la-Neuve, Belgique, 24 mai 2019, 17.35 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir [...]

Pages